The primary clear cell tumor of the lung is an extremely rare benign tumor. This tumor is called “sugar tumor” since clear cell tumor of the lung contains abundant glycogen. We here present a case of lung clear cell tumor of the lung associated to essential thrombocythemia. To the best of our knowledge, there is no report about this association.A 44-Year-Old Woman admitted to our clinic with a 2-month history of fatigue. On physical examination, the spleen was 3 cm palpable below the left costal margin on the mid axillary line. The laboratory tests revealed an elevated platelet counts (1,014,000/mm3). A pulmonary nodule (3,5 cm) was detected in the upper right lobe on the chest X-ray. Then, thoracic computed tomography (CT) was planned. The nodule looked like benign pattern on CT scan and total excision was performed for curative and diagnostic treatment.Microscopically, the tumor was composed of nests of rounded or oval cells with distinct cell borders, optically clear cytoplasm and small nucleus. By immunohistochemistry, tumor cells were positive for HMB-45, NSE and focal S100 antigen. And, it was diagnosed as clear “sugar” cell tumor. After tumor excision the lasting thrombocytosis induced us to perform bone marrow biopsy and JAK2 mutation research.Diagnosis of Essential Thrombocythemia was made. In conclusion, it is important to make an evaluation for myeloproliferative diseases in clear “sugar” cell tumor in adults if thrombocytosis was lasting after treatment.
5199 Reactive oxygen species (ROS) may play a role in ischemia, inflammation, aging, and carcinogenesis. In some studies, it was shown that the metabolism of ROS and lipid peroxidation were stimulated in solid tumors and hematological malignancies. Moreover different results for the levels of protective enzymes from ROS were reported. In this prospective study, the role of ROS, lipid peroxidation, and protective enzymes from ROS were investigated in patients with newly diagnosed hematologic malignancies. Fifty-one patients (33 were male and 18 female, with mean age of 64 ± 15 years) with newly diagnosed and untreated hematological malgnancies were enrolled to this study. Local ethical commity of our university approved this study. 21 of the patients were chronic lymphocytic leukemia (CLL), 18 multiple myeloma (MM) and 12 non-Hodgkin's lymphoma (NHL). 31 healthy individuals (19 were male and 12 female, with mean age of 63±11 years) were selected as control group. The exclusion criteria were diabetes mellitus, malignancy, acute and chronic infections, and chronic inflammatory diseases. 72%, 14%, and 14% of the patients with CLL were in Stage A, Stage B and Stage C, respectively. 17%, 33%, and 50% of patients with MM were in International prognostic index-1 (IPI1), IPI2, and IPI3, respectively. The types of patients with NHL were diffuse large B-cell lymphoma (92%) and mantle cell lymphoma (8%). According to Ann-Arbor staging system, 42% of the patients with NHL were at stage 1, 8% in stage 2, 8% at stage 3, and 42% at stage 4, respectively. When diagnosed, superoxide dismutase (SOD), glutathione peroxidase (Gpx), catalase, total glutathione (GSH), and malondialdehyde (MDA) as the predictor of lipid peroxidation were evaluated in both patients and controls bu spectrophometrical. The results were compared with Student-t, One-way ANOVA, and Chi-square tests. In this study, there is no difference between patient and control groups in terms of age and sex (p>0.05). When evaluated in terms of SOD, MDA, and catalase, no difference was found between control and patient groups (p>0.05). The levels of Gpx in patients with hematological malignancies were significantly lower than control group (p< 0.001). While the levels of Gpx in all patient groups were lower than control (p< 0.001 for all groups), no significant difference was determined between patient groups (p< 0.001). Total GSH levels in patients with hematological malignancies were higher than control group (p<0.001). While GSH levels were higher only in patients with CLL (p<0.05) and MM (p<0.005), there was no difference between patients with NHL and controls (p>0.05). However, the levels of GSH were not different in patient groups (p>0.05). In conclusion, unchanged lipid peroxidation in patients with hematological malignancies may be related to decrease in Gpx and increase in GSH. This condition may be due to inhibition of lipid peroxidation by Gpx in presence of GSH and suppression of lipid peroxidation as protective mechanism of body.Table.The results of patients with hematological malignancies and controlsParametersCLL (21)MM (18)NHL (12)Total (51)Control (31)SOD (pg/g Hb)13.4±7.888.89±2.868.8±3.329.17±2.78.45±2.83MDA (μmol/g Hb)1.58±0.361.63±0.421.68±0.611.62±0.441.66±0.43Gpx (U/g Hb)67.6±36.5***78.8±43.9***80.5±46.1***74.6±41.1***198.54±134.5GSH (mg/g Hb)3.54±0.74*3.8±0.71**3.54±0.873.63±0.82.94±0.56***Catalase (U/g Hb)137.7±52.3137±46.9163±116.2143.4±70.2139.9±62.9*:p<0.05**:p<0.005***:p<0.001 Disclosures: No relevant conflicts of interest to declare.
Giriş Tip 2 diabetes mellitus (DM) tanılı hastalar yaşamları boyunca hastalığa ikincil gelişen komplikasyon ya da hastalık dışı nedenlerden dolayı cerrahi girişimle karşı karşıya kalabilmektedirler. Biz bu çalışmada, Tip 2 DM tanılı hastaların yaşamları boyunca geçirdikleri cerrahi müdahaleleri ve sıklıklarını belirlemeyi amaçladık. Materyal ve MetodTemmuz 2013-Aralık 2013 tarihleri arasında Tip 2 DM tanılı 922 hasta gözlemsel olarak çalışmaya alındı. Hastaların yaş, cinsiyet, ortalama hastalık süreleri, Tip 2 DM tanı öncesi ve sonrasında geçirilmiş operasyon öyküleri ile sayıları değerlendirilmeye alındı ve bilgiler olgu takip formuna kaydedildi.Bulgular Olguların %58.4'ü kadın olup yaş ortalaması 57.36 ±11.1 yıldı. Ortalama hastalık süresi 9.06±7.34 yıl idi. Hastaların %53.3'ü hayatları boyunca en az bir kez cerrahi operasyon geçirmiş olarak saptandı. Tip 2 DM tanısı konulmadan önce en az bir kez cerrahi müdahale geçirme sıklığı %33.7, tanı sonrasında ise %28.1 idi. Diyabet tanısı konulmadan önce en sık geçirilen operasyonların başında apendektomi (%7.1), kolesistektomi (%5.3) ve total abdominal histerektomi-bilateral salpingo ooferoktomi (%3.9) gelmekteydi. Diyabet tanısı konulduktan sonra ise en sık geçirilen operasyonlar sırasıyla kolesistektomi (%5), katarakt (%5), ortopedik cerrahi işlemler (%5) ve koroner arter by-pass cerrahisi (%4.1) idi.Sonuç Çalışmamızda Tip 2 DM tanılı hastaların %53.3'ünün yaşamlarının bir döneminde operasyon geçirdiğini saptadık. Diyabetli hastalarda cerrahi müdahale sıklığının yüksek olması preoperatif değerlendirmenin önemi artırmaktadır.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.